-
公开(公告)号：US07659254B2
公开(公告)日：2010-02-09
申请号：US12201586
申请日：2008-08-29
申请人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
发明人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
IPC分类号： A61K38/00 , A61K51/00 , A61K31/785 , G01N33/53 , G01N33/00
CPC分类号： A61K31/165 , A61K47/542 , C07C237/06 , Y10S436/901 , Y10T436/173845
摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
公开(公告)号：US20090149392A1
公开(公告)日：2009-06-11
申请号：US12203137
申请日：2008-09-02
申请人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
发明人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
IPC分类号： A61K38/08 , A61K31/165 , A61K38/05 , A61P25/26 , A61K38/06
CPC分类号： A61K31/165 , A61K47/542 , C07C237/06 , Y10S436/901 , Y10T436/173845
摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
公开(公告)号：US20090143304A1
公开(公告)日：2009-06-04
申请号：US12202777
申请日：2008-09-02
申请人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Christopher A. Verbicky , Bernhard J. Paul
发明人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Christopher A. Verbicky , Bernhard J. Paul
CPC分类号： A61K31/165 , A61K47/542 , C07C237/06 , Y10S436/901 , Y10T436/173845
摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
公开(公告)号：US20090137677A1
公开(公告)日：2009-05-28
申请号：US12239600
申请日：2008-09-26
申请人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
发明人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
IPC分类号： C07C211/27 , C07H7/00 , C07H21/00 , C07C229/02 , A61K31/135 , A61P25/00 , A61K31/195
CPC分类号： A61K31/165 , A61K47/542 , C07C237/06 , Y10S436/901 , Y10T436/173845
摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
公开(公告)号：US20090137515A1
公开(公告)日：2009-05-28
申请号：US12239364
申请日：2008-09-26
申请人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
发明人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
IPC分类号： C07C229/34 , C07C211/34 , C07H21/00 , C08B37/00 , A61K31/195 , A61K31/70 , A61K31/7088 , A61P25/00
CPC分类号： A61K31/165 , A61K47/542 , C07C237/06 , Y10S436/901 , Y10T436/173845
摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
公开(公告)号：US20090137488A1
公开(公告)日：2009-05-28
申请号：US12203129
申请日：2008-09-02
申请人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
发明人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
IPC分类号： A61K38/08 , C07C229/02 , C07K5/06 , C07K5/08 , C07K5/10 , C07K7/06 , A61P25/00 , A61K31/198 , A61K38/05 , A61K38/06 , A61K38/07
CPC分类号： A61K31/165 , A61K47/542 , C07C237/06 , Y10S436/901 , Y10T436/173845
摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
公开(公告)号：US20090137461A1
公开(公告)日：2009-05-28
申请号：US12239571
申请日：2008-09-26
申请人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
发明人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
CPC分类号： A61K31/165 , A61K47/542 , C07C237/06 , Y10S436/901 , Y10T436/173845
摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
公开(公告)号：US20090131516A1
公开(公告)日：2009-05-21
申请号：US12201794
申请日：2008-08-29
申请人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
发明人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
IPC分类号： A61K31/27 , A61K31/165
CPC分类号： A61K31/165 , A61K47/542 , C07C237/06 , Y10S436/901 , Y10T436/173845
摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
公开(公告)号：US20090131476A1
公开(公告)日：2009-05-21
申请号：US12239429
申请日：2008-09-26
申请人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
发明人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
IPC分类号： A61K47/48 , A61K31/445 , A61K31/137 , A61P25/00
CPC分类号： A61K31/165 , A61K47/542 , C07C237/06 , Y10S436/901 , Y10T436/173845
摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
公开(公告)号：US20090131335A1
公开(公告)日：2009-05-21
申请号：US12239554
申请日：2008-09-26
申请人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
发明人： Travis Mickle , Suma Krishnan , Barney Bishop , Christopher Lauderback , James Scott Moncrief , Robert Oberlender , Thomas Piccariello , Bernhard J. Paul , Christopher A. Verbicky
IPC分类号： A61K38/06 , A61K31/165 , A61P25/00 , A61K38/05
CPC分类号： A61K31/165 , A61K47/542 , C07C237/06 , Y10S436/901 , Y10T436/173845
摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.085 秒)
